Howie Jacqueline, Reilly Louise, Fraser Niall J, Vlachaki Walker Julia M, Wypijewski Krzysztof J, Ashford Michael L J, Calaghan Sarah C, McClafferty Heather, Tian Lijun, Shipston Michael J, Boguslavskyi Andrii, Shattock Michael J, Fuller William
Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, United Kingdom;
School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom;
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17534-9. doi: 10.1073/pnas.1413627111. Epub 2014 Nov 24.
The cardiac phosphoprotein phospholemman (PLM) regulates the cardiac sodium pump, activating the pump when phosphorylated and inhibiting it when palmitoylated. Protein palmitoylation, the reversible attachment of a 16 carbon fatty acid to a cysteine thiol, is catalyzed by the Asp-His-His-Cys (DHHC) motif-containing palmitoyl acyltransferases. The cell surface palmitoyl acyltransferase DHHC5 regulates a growing number of cellular processes, but relatively few DHHC5 substrates have been identified to date. We examined the expression of DHHC isoforms in ventricular muscle and report that DHHC5 is among the most abundantly expressed DHHCs in the heart and localizes to caveolin-enriched cell surface microdomains. DHHC5 coimmunoprecipitates with PLM in ventricular myocytes and transiently transfected cells. Overexpression and silencing experiments indicate that DHHC5 palmitoylates PLM at two juxtamembrane cysteines, C40 and C42, although C40 is the principal palmitoylation site. PLM interaction with and palmitoylation by DHHC5 is independent of the DHHC5 PSD-95/Discs-large/ZO-1 homology (PDZ) binding motif, but requires a ∼ 120 amino acid region of the DHHC5 intracellular C-tail immediately after the fourth transmembrane domain. PLM C42A but not PLM C40A inhibits the Na pump, indicating PLM palmitoylation at C40 but not C42 is required for PLM-mediated inhibition of pump activity. In conclusion, we demonstrate an enzyme-substrate relationship for DHHC5 and PLM and describe a means of substrate recruitment not hitherto described for this acyltransferase. We propose that PLM palmitoylation by DHHC5 promotes phospholipid interactions that inhibit the Na pump.
心肌磷酸化蛋白磷酸受磷蛋白(PLM)调节心肌钠泵,磷酸化时激活该泵,而棕榈酰化时则抑制它。蛋白质棕榈酰化是指将一个16碳脂肪酸可逆地连接到半胱氨酸硫醇上,由含天冬氨酸-组氨酸-组氨酸-半胱氨酸(DHHC)模体的棕榈酰酰基转移酶催化。细胞表面棕榈酰酰基转移酶DHHC5调节越来越多的细胞过程,但迄今为止,已鉴定出的DHHC5底物相对较少。我们检测了心室肌中DHHC同工型的表达,并报告DHHC5是心脏中表达最丰富的DHHC之一,定位于富含小窝蛋白的细胞表面微区。在心室肌细胞和瞬时转染细胞中,DHHC5与PLM共免疫沉淀。过表达和沉默实验表明,DHHC5使PLM在两个近膜半胱氨酸C40和C42处发生棕榈酰化,尽管C40是主要的棕榈酰化位点。PLM与DHHC5的相互作用及棕榈酰化独立于DHHC5的突触后密度蛋白95/盘状大蛋白/紧密连接蛋白1同源(PDZ)结合模体,但需要DHHC5细胞内C末端在第四个跨膜结构域之后的约120个氨基酸区域。PLM C42A而非PLM C40A抑制钠泵,表明PLM介导的泵活性抑制需要C40而非C42处的PLM棕榈酰化。总之,我们证明了DHHC5与PLM之间的酶-底物关系,并描述了一种该酰基转移酶迄今未描述的底物募集方式。我们提出,DHHC5介导的PLM棕榈酰化促进了抑制钠泵的磷脂相互作用。